Study of Dupilumab plus Usual Care vs Usual Care Alone for Adults After COPD Hospitalization

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy of Dupilumab Added on to Standard of Care (SOC) Treatment vs SOC Treatment Following Hospitalization for a COPD Exacerbation

• IRAS ID

  1014002

• Contact name

  Carmen Oltean

• Contact email

  CTRS-UK-Submissions@parexel.com

• Sponsor organisation

  Regeneron Pharmaceuticals, Inc.

• Research summary

  This study is researching a drug called dupilumab, referred to as “study drug”. The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days).

  The study is looking at another research question:
  • What side effects may happen from taking the study drug

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  26/EM/0118

• Date of REC Opinion

  7 Jul 2026

• REC opinion

  Further Information Favourable Opinion